Multiple Sclerosis Information
Search
I would appreciate a donation. I spend a lot of time every day in researching for articles and the latest research on MS. When an something is written in medical terminology I translate it into non-medical terms. I can no longer work because of my MS.
This Month
July 2009
Sun Mon Tue Wed Thu Fri Sat
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31
View Article  Natalizumab associated with pro-inflammatory T cells
Natalizumab is an antibody directed against integrin alpha4 that reduces disease activity in patients with multiple sclerosis (MS) by blocking migration of T and B cells into the Central Nervouse System (CNS). The goal of this study was   more »
View Article  phase III trial of Mylinax (oral cladribine)
Over the two-year period of the study, 80% of the low dose regimen Cladribine arm and 79% of the high-dose regimen arm experienced no clinical relapse, compared with 61% of the   more »
View Article  Drug Trial - Female Stress Urinary Incontinence
Over 11 million women in the United States suffer from stress urinary incontinence (SUI), the involuntary leakage of urine during routine physical activities such as laughing, coughing, exercising, or sneezing. SUI affects women   more »
View Article  U.S. Study Will Test Vitamin D, Fish Oil
Two of the most popular and promising dietary supplements -- vitamin D and fish oil -- will be tested in a large, government-sponsored study to see whether either nutrient can lower a healthy person's risk of getting cancer   more »
View Article  Oral Laquinimod Phase III MS Clinical Trial
Teva Pharmaceutical Industries Ltd. and Active Biotech today announced completion of patient enrollment for the second pivotal Phase III clinical trial, BRAVO, evaluating the novel, oral once-daily immunomodulating   more »
View Article  Study - Spasticity
This research study will evaluate a treatment for moderate to severe spasticity associated with MS. All patients must have been on baclofen for at least four weeks prior to first visit. This study requires   more »
View Article  Study - Restless Legs
Discomfort or pain in your legs which worsens at night or when resting A strong urge to move your legs for relief Itching, pulling, creepy-crawly, tugging, or gnawing   more »
View Article  Clinical Study – Volunteers Needed 2
This is an early phase study designed to test the safety of a compound. This is one of the steps necessary before conducting a large clinical trial to determine if the agent ONO-4641 is effective in MS.   Main Eligibility R   more »
View Article  Clinical Study – Volunteers Needed
A Randomized, Double-blind, Placebo-Controlled, Escalating-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS-0777, Administered   more »
View Article  Clinical Trial - Spasticity
This research study will evaluate a treatment for moderate to severe spasticity associated with MS. All patients must have been on baclofen for at least four weeks prior to first visit. This study requires five visits over   more »
View Article  Study - Restless Leg Syndrome
Make $250.00 - RLS is a disorder of the nervous system affecting movement of the legs, usually interfering with sleep. If you are suffering from this disorder, you may wish to consider a clinical research study of a   more »
View Article  MS Therapies in the Pipeline
It is a time of exciting evolution and expansion in MS research, and there are many potentially life-changing MS therapies that are making their way through the medical pipeline. The Rocky Mountain MS Center, along with other organizations, is committed   more »
View Article  MAESTRO-03 trial of Dirucotide in patients with SPMS
BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of Dirucotide in   more »
View Article  Stem Cell Research Clinical Trial Information
The purpose of this study is to determine the effectiveness of a new treatment for multiple sclerosis (MS), a serious disease in which the immune system attacks the brain and spinal cord. MS can be progressive and severe and lead to significant disability. The study   more »
View Article  Drug Trial BVA-101, Positive Efficacy Results
Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned   more »